Abstract
Purpose of Review
This paper reviews the literature examining antipsychotic prescription disparities between white people and black people.
Recent Findings
Despite literature documenting racial discrepancies in diagnosis, there have been limited studies examining disparities in antipsychotic prescription between white people and black people. Studies have demonstrated that black people are more likely to receive first generation antipsychotics, higher antipsychotic doses, and long acting injectables, but less likely to receive clozapine. Much of this work was done in the early 2000s.
Summary
Future research directions include investigation into why these disparities exist. Literature examining these disparities has focused on genetic and sociological factors; however, the impact of prescriber bias and structural racism remains underexplored. Until the research proceeds, future clinical directions should include empowering patients, families, and clinicians to question practices that may exacerbate these known disparities.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. https://doi.org/10.1093/schbul/sbp116.
Strakowski SM, Shelton RC, Kolbrener ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry. 1993;54(3):96–102.
Strakowski SM, Lonczak HS, Sax KW, West SA, Crist A, Mehta R, Thienhaus OJ. The effects of race on diagnosis and disposition from a psychiatric emergency service. J Clin Psychiatry. 1995;56(3):101–7.
Chinman MJ, Rosenheck RA, Lam JA. Client-case manager racial matching in a program for homeless persons with serious mental illness. Psychiatr Serv. 2000;51(10):1265–72. https://doi.org/10.1176/appi.ps.51.10.1265.
DelBello MP, Lopez-Larson MP, Soutullo CA, Strakowski SM. Effects of race on psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2001;11(1):95–103. https://doi.org/10.1089/104454601750143528.
Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, Russo PA. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. Schizophr Res. 2003;60(2–3):259–69. https://doi.org/10.1016/s0920-9964(02)00223-2.
Barnes A. Race, schizophrenia, and admission to state psychiatric hospitals. Adm Policy Ment Health. 2004;31(3):241–52. https://doi.org/10.1023/b:apih.0000018832.73673.54.
Bresnahan M, Begg MD, Brown A, Schaefer C, Sohler N, Insel B, Vella L, Susser E. Race and risk of schizophrenia in a US birth cohort: another example of health disparity? Int J Epidemiol. 2007;36(4):751–8. https://doi.org/10.1093/ije/dym041.
Barnes A. Race and hospital diagnoses of schizophrenia and mood disorders. Soc Work. 2008;53(1):77–83. https://doi.org/10.1093/sw/53.1.77.
Anglin DM, Malaspina D. Racial and ethnic effects on psychotic psychiatric diagnostic changes from admission to discharge: a retrospective chart review. J Clin Psychiatry. 2008;69(3):464–9. https://doi.org/10.4088/jcp.v69n0318.
Gara MA, Vega WA, Arndt S, Escamilla M, Fleck DE, Lawson WB, Lesser I, Neighbors HW, Wilson DR, Arnold LM, Strakowski SM. Influence of patient race and ethnicity on clinical assessment in patients with affective disorders. Arch Gen Psychiatry. 2012;69(6):593–600. https://doi.org/10.1001/archgenpsychiatry.2011.2040.
Durbin A, Rudoler D, Durbin J, Laporte A, Callaghan RC. Examining patient race and area predictors of inpatient admission for schizophrenia among hospital users in California. J Immigr Minor Health. 2014;16(6):1025–34. https://doi.org/10.1007/s10903-013-9831-7.
Schwartz RC, Blankenship DM. Racial disparities in psychotic disorder diagnosis: a review of empirical literature. World J Psychiatry. 2014;4:133–40. https://doi.org/10.5498/wjp.v4.i4.133.
Coleman KJ, Stewart C, Waitzfelder BE, Zeber JE, Morales LS, Ahmed AT, Ahmedani BK, Beck A, Copeland LA, Cummings JR, Hunkeler EM, Lindberg NM, Lynch F, Lu CY, Owen-Smith AA, Trinacty CM, Whitebird RR, Simon GE. Racial-ethnic differences in psychiatric diagnoses and treatment across 11 health care systems in the mental health research network. Psychiatr Serv. 2016;67(7):749–57. https://doi.org/10.1176/appi.ps.201500217.
Maura J, de Weisman MA. Mental health disparities, treatment engagement, and attrition among racial/ethnic minorities with severe mental illness: a review. J Clin Psychol Med Settings. 2017;24(34):187–210. https://doi.org/10.1007/s10880-017-9510-2.
Olbert CM, Nagendra A, Buck B. Meta-analysis of Black vs. White racial disparity in schizophrenia diagnosis in the United States: do structured assessments attenuate racial disparities? J Abnorm Psychol. 2018;127(1):104–15. https://doi.org/10.1037/abn0000309.
Gara MA, Minsky S, Silverstein SM, Miskimen T, Strakowski SM. A Naturalistic study of racial disparities in diagnoses at an outpatient behavioral health clinic. Psychiatr Serv. 2019;70(2):130–4. https://doi.org/10.1176/appi.ps.201800223.
Wiener HW, Klei L, Irvin MD, Perry RT, Aliyu MH, Allen TB, Bradford LD, Calkins ME, Devlin B, Edwards N, Gur RE, Gur RC, Kwentus J, Lyons PD, McEvoy JP, Nasrallah HA, Nimgaonkar VL, O’Jile J, Santos AB, Savage RM, Go RC. Linkage analysis of schizophrenia in African-American families. Schizophr Res. 2009;109(1–3):70–9. https://doi.org/10.1016/j.schres.2009.02.007.
•• Eack SM, Bahorik AL, Newhill CE, Neighbors HW, Davis LE. Interviewer-perceived honesty as a mediator of racial disparities in the diagnosis of schizophrenia. Psychiatr Serv. 2012;63(9):875–80. https://doi.org/10.1176/appi.ps.201100388. (This paper suggests that clinician perception of the patient strongly influences diagnosis, demonstrating that disparities in schizophrenia diagnosis are influenced by the interviewer’s perception that the patient is not honest during the interview, which appears to occur more frequently in African American patients.)
Davidson JR, Raft D, Lewis BF, Gebhardt M. Psychotropic drugs on general medical and surgical wards of a teaching hospital. Arch Gen Psychiatry. 1975;32(4):507–11. https://doi.org/10.1001/archpsyc.1975.01760220119012.
Rossiter LF. Prescribed medicines: findings from the National Medical Care Expenditure Survey. Am J Public Health. 1983;73(11):1312–5. https://doi.org/10.2105/ajph.73.11.1312.
•• Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159(4):567–72. https://doi.org/10.1176/appi.ajp.159.4.567. (This study is one of the largest in this area, published nearly twenty years ago, examining Medicaid claims records from over 2500 people in 1995)
Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17–29. https://doi.org/10.1093/oxfordjournals.schbul.a006920.
•• Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003;160(10):1817–22. https://doi.org/10.1176/appi.ajp.160.10.1817. (This paper examined prescribing practices among patients receiving care through the Department of Veterans Affairs in 1999, including nearly 70,000 records in their analysis. The authors demonstrated prescribing disparities in both African American and Latino populations)
•• Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, Ford DE. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60(2):121–8. https://doi.org/10.1001/archpsyc.60.2.121. (This paper demonstrated that black people were about half as likely to receive second generation antipsychotics vs first generation antipsychotics compared to white people in a sample of approximately 5000 people over 1992–2000. They examined how the trend changed over time, and while the gap did decrease with each two year period, black people were still less likely to be prescribed second generation antipsychotics in 1998–2000)
Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. J Clin Psychiatry. 2003;64(6):635–9. https://doi.org/10.4088/jcp.v64n0603.
Valenti AM, Narendran R, Pristach CA. Who are patients on conventional antipsychotics? Schizophr Bull. 2003;29(2):195–9. https://doi.org/10.1093/oxfordjournals.schbul.a006997.
•• Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;2:183–93. https://doi.org/10.1093/oxfordjournals.schbul.a006996. (This study used a medical record review of patients recruited from the Patient Outcomes Research Team (PORT) study in a part of the study aimed at understanding variations in treatment among people with schizophrenia)
Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004;55(2):151–6. https://doi.org/10.1176/appi.ps.55.2.151.
•• Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, Snowden LR. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004;55(6):677–84. https://doi.org/10.1176/appi.ps.55.6.677. (The authors suggest that increase prescription of first generation antipsychotics among African Americans leads to an increase in side effects and, in turn, and increase in nonadherence)
Puyat JH, Daw JR, Cunningham CM, Law MR, Wong ST, Greyson DL, Morgan SG. Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2013;48(12):1861–72. https://doi.org/10.1007/s00127-013-0753-4.
Cook TB, Reeves GM, Teufel J, Postolache TT. Persistence of racial disparities in prescription of first-generation antipsychotics in the USA. Pharmacoepidemiol Drug Saf. 2015;24(11):1197–206. https://doi.org/10.1002/pds.3819.
Pan I (2016) Association between race/ethnicity and the receipt of outpatient second-generation antipsychotic agents stratified by metabolic effects. Thesis Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmaceutical Sciences. The University of Texas at Austin August
Lawson W, Johnston S, Karson C, Offord S, Docherty J, Eramo A, Kamat S, Blanchette CM, Carson W, Nasrallah HA. Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry. 2015;27(4):242–52.
De Leon J, Diaz F, Josiassen R, Cooper T, Simpson G. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27(1):22–7. https://doi.org/10.1097/JCP.0b013e31802e513a.
Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1–3):95–102. https://doi.org/10.1016/j.schres.2009.02.006.
Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013;3(1):33–51. https://doi.org/10.1177/2045125312464385.
Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005;181(1):179–87. https://doi.org/10.1007/s00213-005-2223-5.
•• Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry. 1985;142(12):1491–2. https://doi.org/10.1176/ajp.142.12.1491. (Evidence of disparities in long acting injectable use were published as early as 1985, before second-generation antipsychotics came to market)
Chen EY, Harrison G, Standen PJ. Management of first episode psychotic illness in Afro-Caribbean patients. Br J Psychiatry. 1991;158:517–22. https://doi.org/10.1192/bjp.158.4.517.
Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry. 1994;45(1):38–42. https://doi.org/10.1176/ps.45.1.38.
Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull. 1996;32(3):321–6.
Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482–8. https://doi.org/10.1176/ps.2007.58.4.482.
Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT. State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia. Psychiatr Serv. 2014;65(1):121–4. https://doi.org/10.1176/appi.ps.201300001.
Kishimoto T, Sanghani S, Russ MJ, Marsh AN, Morris J, Basu S, John M, Kane JM. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. Int Clin Psychopharmacol. 2017;32(3):161–8. https://doi.org/10.1097/YIC.0000000000000165.
Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J. 2005;41(5):521–37. https://doi.org/10.1007/s10597-005-6359-x.
•• Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–64. https://doi.org/10.1093/oxfordjournals.schbul.a007076. (Using medical records from over 60,000 patients receiving care at the Department of Veterans Affairs, the authors conclude that young, African American people and people taking first generation antipsychotics are most likely to be non-adherent. While a change from a first-generation to second-generation antipsychotic does improve adherence, the improvement was not robust enough to fully explain the disparity)
Mark TL, Palmer LA, Russo PA, Vasey J. Examination of treatment pattern differences by race. Ment Health Serv Res. 2003;4:241–50. https://doi.org/10.1023/a:1026281118990.
Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000;61(5):382–6.
Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1994;29(4):172–7. https://doi.org/10.1007/BF00802014.
Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the health care system. Public Health Rep. 2003;118(4):358–65. https://doi.org/10.1093/phr/118.4.358.
Armstrong K, Ravenell KL, McMurphy S, Putt M. Racial/ethnic differences in physician distrust in the United States. Am J Public Health. 2007;97(7):1283–9. https://doi.org/10.2105/AJPH.2005.080762.
Clark PA. A legacy of mistrust: African-Americans, the medical profession, and AIDS. Linacre Q. 1998;65(1):66–88. https://doi.org/10.1080/00243639.1998.11878407.
Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997;87(11):1773–8. https://doi.org/10.2105/ajph.87.11.1773.
Young AS, Sullivan G, Duan N. Patient, provider, and treatment factors associated with poor-quality care for schizophrenia. Ment Health Serv Res. 1999;1(4):201–11. https://doi.org/10.1023/a:1022369323451.
Aggarwal NK, Rosenheck RA, Woods SW, Sernyak MJ. Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review. J Clin Psychiatry. 2012;73(4):513–7. https://doi.org/10.4088/JCP.11m07161.
Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63–7. https://doi.org/10.1192/bjp.195.52.s63.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, WFSBP Task force on treatment guidelines for schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. https://doi.org/10.3109/15622975.2012.739708.
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.
Kane JM, Zhao C, Johnson BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015;18:145–54.
Taylor D, Olofinjana O. Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014;29:229–34.
Kamat SA, Offord S, Docherty J, et al. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4:1–12. https://doi.org/10.7573/dic.212267.
Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl. 2009;52:S37-42. https://doi.org/10.1192/bjp.195.52.s37.
West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995–1001. https://doi.org/10.1093/schbul/sbm137.
Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, Elliott CE, Booth BM. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual. 2003;18(4):140–6. https://doi.org/10.1177/106286060301800402.
Soleman M, Lam N, Woo BK. Ethnic and age disparities in patients taking long-acting injectable atypical antipsychotics. Cureus. 2017;9(10): e1772. https://doi.org/10.7759/cureus.1772.
Chung H, Mahler JC, Kakuma T. Racial differences in treatment of psychiatric inpatients. Psychiatr Serv. 1995;46(6):586–91. https://doi.org/10.1176/ps.46.6.586.
Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1–10. https://doi.org/10.1093/oxfordjournals.schbul.a033302.
Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry. 2000;61(5):344–8. https://doi.org/10.4088/jcp.v61n0504.
•• Valenstein M, Copeland L, Owen R, Blow F, Visnic S. Delays in adopting evidence-based dosages of conventional antipsychotics. Psychiatr Serv. 2001;52(9):1242–4. https://doi.org/10.1176/appi.ps.52.9.1242. (The authors demonstrate that African American patients are more likely to receive high doses of antipsychotic medications, suggesting that providers are slower or less likely to adhere to evidence-based guidelines in treating African American patients)
dos Reis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull. 2002;28(4):607–17. https://doi.org/10.1093/oxfordjournals.schbul.a006968.
Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66(2–3):169–75. https://doi.org/10.1016/S0920-9964(03)00102-6.
Bakare MO. Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference? BMC Res Notes. 2008;1:25. https://doi.org/10.1186/1756-0500-1-25.
Flaskerud JH, Hu LT. Racial/ethnic identity and amount and type of psychiatric treatment. Am J Psychiatry. 1992;149(3):379–84. https://doi.org/10.1176/ajp.149.3.379.
Dixon L, Lyles A, Smith C, Hoch JS, Fahey M, Postrado L, Lucksted A, Lehman A. Use and costs of ambulatory care services among Medicare enrollees with schizophrenia. Psychiatr Serv. 2001;52(6):786–92. https://doi.org/10.1176/appi.ps.52.6.786.
Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, Brown CH, Conley RR. Clozapine utilization and outcomes by race in a public mental health system: 1994–2000. J Clin Psychiatry. 2006;67(9):1404–11. https://doi.org/10.4088/jcp.v67n0911.
•• Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. 2007;33(5):1221–4. https://doi.org/10.1093/schbul/sbl068. (In this study including 1875 people, more white people developed leucopenia and agranulocytosis of clozapine than black people. The authors advocated for reconsidering the prescribing guidelines to better recognize differences in white blood cell counts between black and white people, a change that ultimately occurred several years later)
Manuel JI, Essock SM, Wu Y, Pangilinan M, Stroup S. Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatr Serv. 2012;63(11):1146–9. https://doi.org/10.1176/appi.ps.201100435.
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65(2):186–92. https://doi.org/10.1176/appi.ps.201300180.
•• Das-Munshi J, Bhugra D, Crawford MJ. Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study. BMC Med. 2018;16(1):55. https://doi.org/10.1186/s12916-018-1035-5. (This study was published after individuals with benign ethnic neutropenia were included as eligible to receive treatment with clozapine)
•• Williams JC, Harowitz J, Glover J, Tek C, Srihari V. Systematic review of racial disparities in clozapine prescribing. Schizophr Res. 2020;224:11–8. https://doi.org/10.1016/j.schres.2020.07.023. (This 2020 review on racial disparities and clozapine prescription is the most extensive summary of the literature to date)
Manu P, Sarvaiya N, Rogozea LM, Kane JM, Correll CU. Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry. 2016;77(7):e909–16. https://doi.org/10.4088/JCP.15r10085.
Richardson CM, Davis EA, Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia. J Clin Psychiatry. 2016;77(11):e1454–9. https://doi.org/10.4088/JCP.15m10315.
Program, C. R, 2016. Important program update (as of 12/16/2016). Clozapine REMS program. Retrieved July 10th 2018.
Horvitz-Lennon M, Volya R, Donohue JM, Lave JR, Stein BD, Normand SL. Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002–2008. Health Serv Res. 2014;49(4):1121–44. https://doi.org/10.1111/1475-6773.12162.
Snowden LR, Cheung FK. Use of inpatient mental health services by members of ethnic minority groups. Am Psychol. 1990;45(3):347–55. https://doi.org/10.1037//0003-066x.45.3.347.
•• Horvitz-Lennon M, Donohue JM, Lave JR, Alegría M, Normand SL. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv. 2013;64(3):230–7. https://doi.org/10.1176/appi.ps.201200041. (This study, which included over 20,000 people, demonstrates that the effectiveness of clozapine is similar across races and remains the most effective antipsychotic for treatment resistant schizophrenia)
Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 2003L;29(3):531–40.
Velligan DI, Carroll C, Lage MJ, Fairman K. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatr Serv. 2015;66:127–33. https://doi.org/10.1176/appi.ps.201300085.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Human and Animal Rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Menand, E., Moster, R. Racial Disparities in the Treatment of Schizophrenia Spectrum Disorders: How Far Have We Come?. Curr Behav Neurosci Rep 8, 179–186 (2021). https://doi.org/10.1007/s40473-021-00236-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40473-021-00236-7